Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610717-23-000208
Filing Date
2023-07-20
Accepted
2023-07-20 17:18:02
Documents
1
Period of Report
2023-07-19

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 4031
  Complete submission text file 0001610717-23-000208.txt   5396
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Issuer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT STE 200 SAN DIEGO CA 92121
Business Address
Chu Yu-Waye (Reporting) CIK: 0001854586 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37587 | Film No.: 231100545